Wavebreakmedia/iStock.
The R21/Matrix-M vaccine has been approved for use in children aged five to 36 months, the group at the highest risk of death from the malaria parasite, which is spread by mosquitoes. The vaccine is the first to exceed the World Health Organization’s target of 75 percent efficacy and has demonstrated high levels of safety in Phase II trials.
Leave a reply